Speaker: An Pang Chieng, M.D., National PI, WARFARIN Study
Iverson Genetics is currently performing a study, supported by The Center for Medicare & Medicaid Services, addressing the question of whether or not genetic information can reduce the incidence of bleeding and clotting adverse events associated with the initiation of Warfarin therapy (one of the most problematic medications in our healthcare systems history). The outcome of this study could potentially influence the manner in which new pharmaceuticals are brought to market.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?